Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 7/20 | 0.38 |
| ▸ | BCHE | P06276 | 4/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2692800 | 0.91 | BCHE (0.37) | TACR1BCHEACHEMAPTCYP2C19 | |
| SCHEMBL2694556 | 0.91 | BCHE (0.37) | TACR1BCHEACHEMAPTCYP2C19 | |
| SCHEMBL2692797 | 0.80 | SLC6A2 (0.48) | BCHEACHEMAPTCYP2C19PDPK1 | |
| SCHEMBL2692917 | 0.79 | PDPK1 (0.37) | BCHEACHEMAPTCYP2C19PDPK1 | |
| SCHEMBL12118272 | 0.71 | PDPK1 (0.39) | TACR1BCHEACHEMAPTCYP2C19 | |
| SCHEMBL12118185 | 0.71 | MAPT (0.43) | TACR1BCHEACHEMAPTCYP2C19 | |
| SCHEMBL20147259 | 0.70 | SLC6A2 (0.52) | BCHEACHEMAPTCYP2C19PDPK1 | |
| SCHEMBL12162838 | 0.70 | SLC6A2 (0.52) | BCHEACHEMAPTCYP2C19PDPK1 | |
| SCHEMBL13402499 | 0.70 | PDPK1 (0.43) | TACR1BCHEACHEPDPK1MTOR | |
| SCHEMBL21510398 | 0.69 | PDPK1 (0.55) | TACR1BCHEACHEPDPK1MTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088904-B2 | Tetrahydropyran nucleic acid analogs | ISIS PHARMACEUTICALS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| US-20090092981-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | IONIS PHARMACEUTICALS, INC. | 2009-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090092981-A1 | TETRAHYDROPYRAN NUCLEIC ACID ANALOGS | HNRNPM, POLM, RNMT | TACR1 4288/4885BCHE 4560/4885ACHE 4388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.